Obtained effect size as a function of sample size in approved antidepressants: A real-world illustration in support of better trial design

International Clinical Psychopharmacology

Volumn 27, Issue 2, 2012, Pages 100-106

  Gibertini, Michael ^a   Nations, Kari R ^b   Whitaker, John A ^a  

^a SYNEOS HEALTH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antidepressants; Effect size; Meta analyses; Sample size

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE; VILAZODONE;

ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL (TOPIC); EFFECT SIZE; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK; SAMPLE SIZE; STATISTICAL ANALYSIS;

ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONTROLLED CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; HUMANS; NEUROTRANSMITTER UPTAKE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLING STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856409203     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834f504f     Document Type: Article

References (27)

1. Baldwin D, Thompson C (2003). The future of antidepressant pharmacotherapy. World Psychiatry 2:3-8.
2. Begley S (2010). The depressing news about antidepressants: studies suggest that the popular drugs are no more effective than a placebo. In fact, they may be worse. Newsweek.
3. Bostwick JM, Pankratz VS (2000). Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157:1925-1932.
4. Center for Drug Evaluation and Research (2011). Drugs@FDA: FDA approved drug products [Online]. Rockville, MD: Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction =Reports.ReportsMenu [Accessed 12 May 2011].
5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials 7:177-188. (Pubitemid 17189972)
6. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115-127. (Pubitemid 36469860)
7. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. (2010). Anti-depressant drug effects and depression severity: a patientlevel meta-analysis. JAMA 303:47-53.
8. Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, et al. (2008). The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry 69: 1513-1528.
9. Guze SB, Robins E (1970). Suicide and primary affective disorders. Br J Psychiatry 117:437-438.
10. Hedges LV, Olkin I (1985). Statistical methods for meta-analysis. New York: Academic Press.
11. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105. (Pubitemid 37432885)
12. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W (2004). Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 161:2045-2049. (Pubitemid 39441405)
13. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C (2007). Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiatry 62:65-71. (Pubitemid 46898225)
14. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011). Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US food and drug administration in support of new drug applications. J Clin Psychiatry 72:464-472.
15. Kobak KA, Kane JM, Thase ME, Nierenberg AA (2007). Why do clinical trials fail? The problem of measurement error in clinical trials. Time to test new paradigms? J Clin Psychopharmacol 27:1-5. (Pubitemid 46105756)
16. Laughren TP (2001). The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: and FDA perspective. Eur Psychiatry 16:418-423. (Pubitemid 33101277)
17. Leon AC (2000). Placebo protects subjects from nonresponse: a paradox of power. Arch Gen Psychiatry 57:329-330. (Pubitemid 30202322)
18. Leon AC, Marzuk PM, Portera L (1995). More reliable outcome measures can reduce sample size requirements. Arch Gen Psychiatry 52:867-871.
19. Liu KS, Snavely DB, Ball WA, Lines CR, Reines SA, Potter WZ (2008). Is bigger better for depression trials? J Psychiatr Res 42:622-630. (Pubitemid 351626061)
20. Muller MJ, Szegedi A (2002). Effects of interrater reliability of psychopathologic assessment on power and sample size calculations in clinical trials. J Clin Psychopharmacol 22:318-325. (Pubitemid 34546848)
21. Papakostas GI, Fava M (2009). Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19:34-40.
22. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry 62:1217-1227. (Pubitemid 350060895)
23. Targum S (2006). Evaluating rater competency for CNS clinical trials. J Clin Psychopharmacol 26:308-310. (Pubitemid 43804623)
24. Trivedi MH, Rush AJ, Wisniewski SR (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR-D: implications for clinical practice. Am J Psychiatry 163:28-40. (Pubitemid 43050100)
25. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358:252-260.
26. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287:1840-1847. (Pubitemid 34303629)
27. World Health Organization (2001). The World HealthRreport 2001 Mental Health: new understanding, new hope. Geneva: World Health Organization.